SUMMARY DNMT3A mutations occur in $25% of acute myeloid leukemia (AML) patients. The most common mutation, DNMT3A R882H , has dominant negative activity that reduces DNA methylation activity by $80% in vitro. To understand the contribution of DNMT3A-dependent methylation to leukemogenesis, we performed whole-genome bisulfite sequencing of primary leukemic and non-leukemic cells in patients with or without DNMT3A R882 mutations. Nonleukemic hematopoietic cells with DNMT3A R882H displayed focal methylation loss, suggesting that hypomethylation antedates AML. Although virtually all AMLs with wild-type DNMT3A displayed CpG island hypermethylation, this change was not associated with gene silencing and was essentially absent in AMLs with DNMT3A R882 mutations. Primary hematopoietic stem cells expanded with cytokines were hypermethylated in a DNMT3A-dependent manner, suggesting that hypermethylation may be a response to, rather than a cause of, cellular proliferation. Our findings suggest that hypomethylation is an initiating phenotype in AMLs with DNMT3A R882 , while DNMT3A-dependent CpG island hypermethylation is a consequence of AML progression.
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In Brief
Analysis of patient-derived samples shows that CpG island hypermethylation is a consequence of AML progression rather than a driver of transcriptional gene silencing during leukemogenesis.
INTRODUCTION
Altered epigenetic states are a common feature of all cancer types. The most well-studied epigenetic modification in primary cancer samples is DNA methylation, which is known to display characteristic changes in malignant cells compared to normal tissue. These include diffuse hypomethylation (Feinberg and Vogelstein, 1983a; Gama-Sosa et al., 1983) and focal methylation changes at discrete loci (Feinberg and Vogelstein, 1983b) . In some cases, hypomethylation or hypermethylation can be associated with activation and/or repression of specific genes related to cancer pathogenesis (Baylin et al., 1986; Greger et al., 1989; Sakai et al., 1991) . However, genome-wide studies of DNA methylation in a variety of cancer types have shown that cancer-associated methylation changes are widespread (De Carvalho et al., 2012; Figueroa et al., 2010; Hansen et al., 2011) . Because many of these methylation changes are not associated with specific alterations in gene expression, the functional implications of these findings are unclear. Moreover, little is known about how the vast majority of these changes emerge and whether they represent a cause, or a consequence, of cancer development (Baylin and Bestor, 2002) .
Recent sequencing studies have shed light on this question by demonstrating that some tumor cells have mutations that affect DNA methylation pathways. In acute myeloid leukemia (AML), $25% of patients have mutations in DNMT3A, which encodes one of the two known mammalian DNA methyltransferases responsible for de novo cytosine methylation. More than half of these mutations occur at position R882 (predominantly R882H), which yields a mutant protein that prevents the formation of the catalytically active, wild-type DNMT3A homotetramers (Russler-Germain et al., 2014) . Although redundancy may be provided by the other de novo DNA methyltransferase (DNMT3B), expression analysis has shown that this gene is rarely expressed in a functional form in AML cells, suggesting that most de novo methylation activity in these cells is provided by DNMT3A. Indeed, studies of DNA methylation in primary AML samples have shown that DNMT3A R882 mutations (e.g., R882H, R882C, R882P) are associated with focal hypomethylation of specific CpGs when compared to those with wild-type DNMT3A (Russler-Germain et al., 2014) , and conditional knockout mice lacking both Dnmt3a and Dnmt3b show few additional methylation changes in hematopoietic cells, compared to mice that lack only Dnmt3a .
These observations implicate DNMT3A as an important mediator of DNA methylation phenotypes in AML cells. However, little is known about how DNMT3A contributes to specific methylation patterns in AML samples and what genomic contexts are associated with hypomethylation in AMLs with DNMT3A R882 . In addition, although substantial evidence suggests that DNMT3A mutations occur early in leukemia development (Genovese et al., 2014; Jaiswal et al., 2014; Shlush et al., 2014; Xie et al., 2014) , it is not yet clear whether they cause methylation changes in pre-leukemic cells. More generally, the mechanisms by which either DNMT3A mutations-or DNMT3A-dependent DNA methylation changes-contribute to leukemia development are currently unknown. Studies in mice have demonstrated that Dnmt3a deficiency in hematopoietic stem/progenitor cells (HSPCs) is associated with methylation changes in certain genomic contexts . Conditional Dnmt3a null HSPCs also displayed enhanced self-renewal and impaired differentiation (Challen et al., 2011) and can ultimately give rise to lethal hematopoietic malignancies, including AML (Celik et al., 2015; Mayle et al., 2015) . However, these models have not yet provided a direct causal link between specific DNMT3A-dependent methylation changes and leukemia development or explained the DNA methylation landscapes observed in primary human AML samples.
Because DNMT3A provides nearly all of the de novo DNA methylation activity in AML cells, comparisons of methylation from patients with and without DNMT3A R882 mutations provide an opportunity to understand the influence of functional DNMT3A on genome-wide methylation patterns and how the DNMT3A R882 mutations alter these phenotypes in AML cells. In this study, we performed a comprehensive epigenomic analysis of both primary human AML samples and primary human nonleukemic cells with and without the DNMT3A R882H/C mutation to characterize DNMT3A-dependent methylation in AML cells and to better understand the functional consequences of this mutation in hematopoietic cells.
RESULTS

Focal Methylation Loss Occurs in Non-leukemic Hematopoietic Cells from a Patient with a Constitutive
Previous studies have demonstrated that DNMT3A R882 mutations in primary AML samples are associated with focal hypomethylation in specific regions of the genome (Cancer Genome Atlas Research Network, 2013; Russler-Germain et al., 2014) . However, it is not yet known whether this mutation causes hypomethylation in non-leukemic cells prior to the development of AML. To address this question, we obtained blood and skin samples from a 9-year-old patient with tall stature, macrocephaly, dysmorphic features, and global developmental delay, consistent with Tatten-Brown-Rahman Syndrome (TBRS; OMIM #615879), recently shown to be associated with constitutional DNMT3A mutations (Tatton-Brown et al., 2014) . Exome sequencing of DNA from this patient's peripheral blood cells and a skin biopsy identified a heterozygous DNMT3A R882H allele in both tissues ( Figure S1A ), confirming the diagnosis of TBRS. Complete blood counts and morphological analysis of a peripheral blood smear from the patient demonstrated no hematologic abnormalities, and exome sequencing of paired blood and skin DNA did not show any evidence for clonal hematopoiesis (data not shown).
To identify DNMT3A-dependent methylation changes in nonleukemic cells from this patient, we purified peripheral blood polymorphonuclear cells (PMNs), monocytes, and T cells for methylation analysis by whole-genome bisulfite sequencing (WGBS). We also generated control data for the same sorted cell populations from the patient's 13-year-old healthy sibling, who was wild-type for DNMT3A (see Figure S1A ). We first determined the global impact of the DNMT3A R882H allele by comparing methylation levels in the TBRS samples to the sibling's cells. Although global methylation levels were largely unaltered ( Figure S1B ), mean methylation levels were modestly, but significantly, lower across all measured CpGs, as well as those in annotated CpG islands and island shores (within 4 kbp of CpG islands) ( Figures  1A and 1B) . However, hypomethylation was not observed at repetitive elements such as L1 LINE repeats ( Figure 1C ). We next used established methods (Jü hling et al., 2016) to identify differentially methylated regions (DMRs) between the TRBS patient and his sibling using all three peripheral blood cell populations. This analysis identified 4,054 DMRs with >10 CpGs and a mean methylation difference >0.2 (false discovery rate [FDR] <0.05; Figure 1D ), which encompassed only 0.45% of all CpGs. Of these DMRs, 99% (4,001) were hypomethylated in the TBRS patient, verifying that the DNMT3A R882H allele impairs DNA methylation in primary hematopoietic cells. These DMRs were enriched in CpG islands, island shores, and gene promoters ( Figure S1C ), as well as in regions flanking unmethylated CpGs that were conserved in all cell populations from both the TBRS patient and his sibling (unmethylated regions [UMRs] , N = 22,629; see the STAR Methods), which is consistent with previous reports of Dnmt3a activity detected at the edges of See also Figure S1 and Table S1 .
unmethylated regions (a.k.a. methylation ''canyons'') in murine hematopoietic stem cells . Methylation patterns at these DMRs were highly conserved in PMNs, monocytes, and T cells (Figures 1E and 1F) , with the TBRS patient having low methylation values and all cell types from the sibling having higher methylation values (e.g., >73% of DMRs had a mean methylation >0.6 in all samples from the sibling; Figure 1F) . Surprisingly, RNA sequencing (RNA-seq) analysis of unfractionated peripheral blood leukocytes (65% PMNs, 31% lymphocytes, 2% monocytes in the TBRS patient, and 46% PMNs, 36% lymphocytes, 13% monocytes in the sibling) showed that genes with either promoter (N = 1,163) or gene body (N = 2,078) DMRs had similar expression levels ( Figures 1G and  S1D ). Further, no clear trends were observed upon more comprehensive comparisons of expression versus methylation differences in promoters and gene bodies across all expressed genes ( Figures 1H and S1E ).
Whole-Genome Bisulfite Sequencing of Primary AML Samples with DNMT3A R882H/C Mutations Demonstrates Focal Hypomethylation in CpG Dense Regions We next performed whole-genome bisulfite sequencing (WGBS) using total bone marrow cells from AML patients with and without DNMT3A R882H/C mutations to determine the contribution of DNMT3A to DNA methylation in AML cells (Table S1) . For this comparison, we selected four normal karyotype AML samples with heterozygous DNMT3A R882 mutant alleles (including three with R882H and one with R882C) in virtually all leukemic cells ( Figure 2A ) and four normal karyotype AML samples with no DNMT3A mutations detected. The AML samples displayed the expected expression patterns of DNMT3A and DNMT3B (Figure S2A) and were well-matched for patient age (that ranged from 31 to 66), morphological features (i.e., French-AmericanBritish subtype), and NPMc mutations and all were wild-type for IDH1, IDH2, and TET2 (see Table S1 ).
We first assessed the effects of the DNMT3A R882H/C allele on methylation by comparing the methylation levels of DNMT3A 2C ). Similar findings were present at CpGs in gene promoters ( Figure 2D ), but not at repetitive elements such as L1 LINE sequences ( Figure 2E ), where both AML types were equally hypomethylated relative to normal CD34 cells.
We next defined differentially methylated regions (DMRs) between the DNMT3A R882H/C and DNMT3A WT AML samples (using the same methods as described above). We detected 3,898 autosomal DMRs (>10 CpGs, mean methylation difference >0.2, FDR <0.05; Figure 2F ), which spanned an average of 541 bp and 30 CpGs ( Figure S2C ). Of these DMRs, 99% (3,846/3,898) were hypomethylated in the DNMT3A
R882H/C
AMLs from this study, and the majority of the CpGs contained within these loci were also hypomethylated in AMLs with DNMT3A R882H using 450K methylation array data from the TCGA AML study ( Figure S2D ). The AML DMRs were highly enriched for CpG dense regions, with $54% of the CpGs in DMRs occurring in CpG islands ( Figure S2E, ). See also Figure S2 and Table S1. either hypomethylated or hypermethylated by comparing the mean methylation of each DMR from each AML set (DNMT3A WT or DNMT3A R882H/C ) to normal CD34 cells and then assigning the DMR to one of the two categories based on these relationships ( Figure 4A ; see the STAR Methods). This resulted in 1,087 (28%) DMRs that were classified as hypomethylated: methylation in DNMT3A WT AMLs and CD34 cells was similar for these DMRs, and only DNMT3A R882H/C AMLs were hypomethylated ( Figures 4B and S4A ). There were 2,759 (71%) hypermethylated DMRs that displayed increased methylation in the DNMT3A WT AMLs compared with CD34 cells and DNMT3A R882H/C AMLs ( Figures 4C and S4B ). These assignments were virtually unchanged when methylation data from individual CD34 samples or other myeloid cell types were used as the control group, such as promyelocytes, PMNs, or monocytes ( Figure S4C ), indicating that variables such as age and the myeloid differentiation state are unrelated to the relationships between methylation in the AML samples and normal hematopoietic cells at these loci. DMRs classified as hypermethylated were 2.8-fold more likely to occur in annotated CpG islands (64% of hypermethylated DMRs versus 23% of hypomethylated loci; p < 10 À16 , chi-square test; Figure S4D ) and were associated with methylation canyons and gene promoters. Hypomethylated loci were methylated in CD34 cells and were less closely linked to these genomic features ( Figure S4D ). We next examined whether hypomethylated and hypermethylated loci were correlated with specific epigenetic features present in the AML samples in this study. We analyzed epigenetic datasets from DNMT3A R882H/C and DNMT3A WT AMLs, including chromatin immunoprecipitation sequencing (ChIP-seq) data for histone H3K4 mono-methylation, H3K4 and H3K27 tri-methylation, and chromatin accessibility defined by transposaseaccessible chromatin using sequencing (ATAC-seq) (Buenrostro et al., 2013) , as well as previously published datasets from normal CD34 cells (Bernstein et al., 2010) . These data were combined to produce a set of ''conserved'' regions with each epigenetic mark in CD34 cells and both sets of AML samples (Table S2; see the STAR Methods). The majority of all DMRs (3,403/ 3,898, 87%) overlapped at least one conserved region in this dataset. However, there were clear differences in the types of regions associated with hypomethylated versus hypermethylated DMRs ( Figure 4D ). For example, hypomethylated DMRs were statistically associated with H3K4 mono-methylation and accessible chromatin (simulation-based p = 0.0001; Figures See also Figure S3 and Table S1 .
DMR-associated enhancers contained H3K4 mono-methylation signals that were high enough to be classified as ''super-enhancers'' (Whyte et al., 2013) ( Figure S4E ), most had relatively modest signals and were not associated with expression changes (see below). Alternatively, hypermethylated loci overlapped regions with both H3K4 and H3K27 tri-methylation (simulation-based p = 0.0001), which suggests that these may represent bivalent promoter regions ( Figures 4D and 4E ). Together, these results indicate that DNMT3A-dependent methylation changes co-localize with other epigenetic modifications, and regions with hypomethylation versus hypermethylation tend to occur at regions with distinct genomic and epigenomic features in hematopoietic cells.
DNMT3A
R882H/C -Associated Hypomethylation Does Not Dramatically Alter the Epigenetic States or Transcriptional Activities of Nearby Genes
We next compared histone methylation signals, chromatin accessibility, and transcriptional activity between DNMT3A R882H/C and
DNMT3A
WT AMLs to determine whether methylation changes at DNMT3A-dependent loci are associated with altered epigenetic modifications or gene expression. Comparisons of normalized histone methylation and chromatin accessibility signals demonstrated subtle differences between the DNMT3A R882H/C and DNMT3A WT AMLs in regions near DMR loci ( Figure 5A ). Statistical analysis also showed that signal intensities at histone methylation peaks that overlapped DMRs were skewed toward higher values in the DNMT3A R882H/C AMLs; similar skewing was also observed for chromatin accessibility data, although to a lesser extent . Interestingly, epigenetic data from CD34 cells at the both hypomethylated and hypermethylated DMR loci displayed patterns that were more similar to DNMT3A R882H/C AMLs than DNMT3A WT AMLs ( Figure 5A ), implying that the methylation state of DNMT3A R882H/C AMLs may be more ''stem-like.'' However, most of the differences were <2-fold, implying that the DNA methylation differences at these regions have only modest influences on these other epigenetic modifications.
To determine whether DNMT3A-dependent methylation changes influence local transcriptional activity, we performed RNA-sequencing of both total RNA and small RNAs from the same DNMT3A R882H/C and DNMT3A WT AML samples used for all previous analyses. Differential expression analysis identified only 153 differentially expressed genes between the two groups (FDR <0.05, fold change >2, Figure 5B ; Table S3 ). Of the differentially expressed genes, only 18 had promoters that overlapped at least one DNMT3A-dependent DMR; these genes had both higher and lower expression values in DNMT3A R882H/C AMLs (12 up versus 6 down; Figure S5E ). An additional 23 of the differentially expressed genes had either intragenic DMRs (N = 21) and/or DMRs in potential enhancer loci located within 50 kbp from the gene promoter (N = 2), which were also divided between higher and lower expression in the DNMT3A R882H/C AMLs (5 were up and 18 were down; see Table S3 ). Differential expression analysis to detect altered exon usage (Li et al., 2015) between the AML groups identified only 149 unique genes with evidence of abnormal exon skipping or retention in DNMT3A R882H/C AMLs. However, no specific splicing patterns were apparent (i.e., exon retention and skipping were nearly equally observed), and few of the genes were associated with DMRs (32/149; Table S4 ). Data from small RNA species were also analyzed for differential expression, which yielded only eight DMR-associated small RNAs, none of which were differentially expressed ( Figure 5C ). Both the genes with promoter DMRs and the complete set of 153 differentially expressed genes failed to distinguish AML samples with DNMT3A R882H/C mutations from normal karyotype AMLs with wild-type DNMT3A from the TCGA dataset ( Figures S5F and S5G ) and showed only minimal overlap with genes identified using AMLs with and without DNMT3A R882 mutations from the TGCA dataset (e.g., 11 of 153 differentially expressed genes identified here were also among 228 genes identified using 74 intermediate risk AML samples from Russler-Germain et al., [2014] ) suggesting that the small gene expression changes identified in this study are unlikely to be a general feature of DNMT3A R882H/C -mutated AML samples.
To identify more subtle expression differences that might result from altered methylation, we next analyzed the expression of all genes with either promoter (N = 1,366), gene body (N = 1,904), or potential enhancer (N = 544) DMRs. Most these genes had detectable expression in the AML samples and CD34 cells (>94% of the genes had a mean expression above the 25 th percentile), and genes associated with hypomethylated and hypermethylated DMRs displayed a similar range of expression values ( Figure S5H ) and did not result in clustering of AML samples by DNMT3A mutation status ( Figures 5D and S5I) . Furthermore, analysis of all expressed genes failed to demonstrate any trends in expression that correlated with differences in methylation in promoters or gene bodies (Figures 5E and S5J) . Importantly, specific genes previously reported to be dysregulated by the overexpression of DNMT3A R882H and/or the loss of Dnmt3a in mice (Guryanova et al., 2016; Jeong et al., 2014; Rau et al., 2016) were not different between the primary human DNMT3A R882H/C and DNMT3A WT AMLs in this study, or in the TCGA dataset (Figures 5F and S5K), demonstrating that DNMT3A R882H/C AMLs do not have an easy-to-define expression phenotype despite the presence of significant differences in methylation at some linked promoters. (Table S1 ) to normal CD34 cells to define the loci that consistently gain methylation during AML development; we then assessed the methylation status of these regions in DNMT3A R882H/C AMLs. This analysis identified a total of 7,083 DMRs (>10 CpGs, FDR <0.05, methylation difference >0.2), of which 4,912 (69%) were hypermethylated in the DNMT3A WT AML samples relative to the CD34 cells ( Figure 6A ). These loci were also hypermethylated relative to other normal hematopoietic cells (Figure S6A ), and the methylation levels at DMR loci Figure 6B ; via chi-square test FDR <0.05 on summed methylation counts for each DMR). Figure 6C shows that these loci are hypermethylated to varying degrees across a spectrum of DNMT3A
DNMT3A-Dependent Hypermethylation of CpG
WT AML samples, but that this effect was attenuated in nearly all AMLs with R882 mutations ( Figure S6A ).
Because CpG island hypermethylation in cancer is thought to be associated with gene silencing, we next determined whether hypermethylated DMRs in DNMT3A
WT AMLs influenced the expression of nearby genes. The hypermethylated DMRs identified in these samples occurred in the promoters of 2,086 annotated genes, of which 1,366 (65%) had essentially undetectable expression in both the AML samples and normal CD34 cells (<10 mean raw reads). The remaining 720 genes with measureable expression showed marked variability among DNMT3A WT AML samples compared to CD34 cells. Importantly, they did not display a consistent trend toward lower expression despite having increased promoter methylation ( Figure 6D ). Although 130 of the genes with hypermethylated promoter DMRs met genomewide statistical criteria for differential expression between DNMT3A WT AMLs and CD34 cells (FDR <0.05, fold change >2; Table S5 ), expression of these genes was both up (N = 76) and down (N = 54) in the DNMT3A WT AML samples and showed similar expression variability in DNMT3A R882H/C AMLs, which had substantially lower levels of promoter methylation (Figure 6D) . A similar lack of expression differences was observed among genes with hypermethylated DMRs in other regions, including gene bodies (N = 2,384) and distal regulatory elements (N = 136) marked by H3K4 mono-methylation and accessible chromatin ( Figures S6C and S6D) .
Examples of expression and promoter methylation correlations for specific genes are shown in Figure 6E from DNMT3A WT and DNMT3A R882H/C AMLs, as well as CD34 cells. Although a few genes displayed evidence for lower expression in samples with higher methylation values (ZNF300 and MAP3K13, left panels), this anticorrelation was the exception, rather than the rule (e.g., only 4 of the 730 genes with hypermethylated promoter DMRs showed a statistically significant anticorrelation between expression and promoter methylation). Some genes were either repressed or activated in most AML samples, regardless of methylation status (NECAB1, WT1 in Figure 6E ). However, the expression of most genes was not correlated at all with the level of promoter methylation (NSD1, HOXA4 in Figure 6E ). The expression levels of these genes in the DNMT3A R882 AML samples was highly informative, often revealing that apparent gene silencing was related not to promoter methylation per se, but to the AML ''state'' itself (see NECAB1 as a highly representative example). Regardless, most CpG island promoter hypermethylation events were not specifically associated with gene repression in AML samples in this dataset.
DNMT3A-Mediated CpG Island Hypermethylation
Occurs in Non-leukemic Cells during Cytokine-Induced Proliferation In Vitro These data suggested that DNMT3A-dependent CpG island hypermethylation might not be causally related to AML development and might therefore occur in nonmalignant cells under certain conditions (e.g., during periods of rapid cellular proliferation). To test this hypothesis, we used an in vitro culture system to expand individual primary human HSPCs from an AML patient (patient 868442) with a persistent DNMT3A R882H mutation in a long-term remission following treatment with standard induction therapy and high-dose cytarabine consolidation (Figure 7A) . The DNMT3A R882H mutation was present in only a subset of his remission bone marrow cells ($34% based on digital sequencing; Figure S7A ), so we used single-cell sorting to purify 334 individual CD34 + /CD38
À cells from a cryopreserved bone marrow aspirate for expansion in culture with hematopoietic cytokines (G-SCF, SCF, FLT3L, TPO, and IL-3) to cause maximal proliferation of myeloid stem/progenitor cells. We obtained 44 clonally derived cell populations that were genotyped for the DNMT3A R882H allele: 20/44 (45%) possessed the mutation. The remaining clones were wild-type for DNMT3A, thereby providing isogenic cell populations with and without the DNMT3A R882H allele. Following this expansion, no differences were observed in the cell numbers or phenotypic characteristics between the DNMT3A WT and DNMT3A R882H cell populations ( Figure S7B ). The frequency of mutant clones was similar to that of the DNMT3A R882H -positive cells in starting sample (45% versus 34% in the bulk sample), indicating that the DNMT3A R882H allele had a minimal effect on the proliferation and maturation of cells using these culture conditions. Wholegenome sequencing of DNA from the DNMT3A WT and DNMT3A R882H cell pools verified that the DNMT3A R882H pool possessed only the DNMT3A R882H mutation and four other non-recurring, non-coding passenger mutations, confirming that these cells represented the ancestral DNMT3A mutant clone of this tumor. See also Figure S4 and Tables S1 and S2. (E) Expression versus methylation difference plots for all expressed genes between DNMT3A R882H/C and DNMT3A WT AMLs.
(F) Expression of specific genes previously reported to be dependent on functional DNMT3A in AML patients or mouse models (Guryanova et al., 2016; Jeong et al., 2014; Rau et al., 2016; Yan et al., 2011) , using data obtained in this study. p values for each comparison (via t test) are indicated above the columns. See also Figure S5 and Tables S1, S2 , S3, and S4. (E) Expression and DMR methylation values for six genes with hypermethylated promoter CpG islands, including samples from normal CD34 cells (n = 2), DNMT3A WT AMLs (n = 13), and DNMT3A R882H/C AMLs (n = 4), which show variable patterns of expression and promoter methylation.
See also Figure S6 and Tables S1 and S5 .
Differential methylation analysis of WGBS data from the DNMT3A R882H and DNMT3A WT cell pools identified 1,407
DMRs, all of which were hypomethylated in the R882H cell pool ( Figure S7C ). This number was substantially greater than the number of DMRs detected between different cell types from a single normal donor (between 6 and 72 DMRs; data not shown), suggesting that the DNMT3A R882H mutation was directly responsible for these differences. Comparison of methylation at these DMRs to CD34 cells identified 710 of the 1,407 loci (50%) with methylation loss in the cells with DNMT3A R882H ( Figure 7C ). Figure 7F ). These DMRs were enriched for CpG islands ( Figure S7E ) and were not hypermethylated in the expanded cell pool with DNMT3A R882H , suggesting that this proliferationassociated epigenetic phenotype depends on normal DNMT3A activity. Furthermore, these DMRs were also hypermethylated in AMLs with wild-type DNMT3A ( Figures 7G and 7H ), implying that DNMT3A activity is being influenced by similar factors in both leukemic and non-leukemic cells that are under proliferative stress. RNA-seq analysis also showed that genes with hypermethylated DMRs in either promoters (N = 232) or gene bodies and enhancers (N = 487) were expressed at similar levels between the DNMT3A R882H and DNMT3A WT cell pools ( Figures 7I and   S7F ), and no trends were apparent upon analysis of expression versus methylation differences in either the promoters or bodies of all genes ( Figures 7J and S7G) . Interestingly, expression of DNMT3A in the expanded cell populations, which consisted of mature myelomonocytic cells, was 2-to 4-fold higher than in purified myelomonocytic cells from normal donors, with an expression level that was similar to CD34 cells ( Figure 7K ). This suggests that CpG island hypermethylation may be due, at least in part, to upregulation of DNMT3A expression in the highly proliferative non-leukemic cells and is therefore not a leukemia-specific phenomenon.
DISCUSSION
Cancer cells exhibit profound changes in DNA methylation compared to normal cells, but how these changes arise-and how they contribute to the development of cancer-remains unclear. In AML, the importance of DNA methylation in leukemogenesis is underscored by the fact that dominant negative R882H mutations in DNMT3A are the most common initiating mutations for this disease. DNMT3A also appears to provide most of the de novo DNA methylation activity in both normal hematopoietic and AML cells, implying that leukemia-associated DNA methylation changes result from an altered activity of this enzyme. Here, we took advantage of these facts to investigate the contribution of DNMT3A to the origin and patterns of DNA methylation in primary AML cells. The central question addressed in this study is whether leukemia-associated DNA methylation changes represent a cause-or a consequence-of leukemogenesis (Baylin and Bestor, 2002) . Our data suggest that one of the most characteristic cancerassociated methylation changes, CpG island hypermethylation, occurs as a consequence of rapid cellular proliferation and is therefore not a cancer-specific phenomenon. We also found that CpG island hypermethylation in DNMT3A
WT AML cells was dramatically reduced in AML samples with DNMT3A R882H/C mutations, implying that these methylation changes are mediated by DNMT3A and are not required for the development of AML. Further, hypermethylation occurred in normal cells with wildtype DNMT3A during rapid ex vivo expansion driven by cytokines, but not in isogenic cells with DNMT3A R882H from the same patient. Together, these findings suggest that leukemia-associated CpG island hypermethylation is not a pathogenic event in AML development but instead may reflect a response to proliferation that is mediated by DNMT3A. Our study also demonstrates that focal hypomethylation occurs in primary human hematopoietic cells with the DNMT3A R882H mutation in the absence of leukemia. We observed focal methylation loss in cells from a patient with a See also Figure S7 and Table S1 .
constitutional DNMT3A R882H allele who had no evidence of hematopoietic abnormalities and also in non-leukemic, remission bone marrow cells containing a DNMT3A R882H mutation. Indeed, in the analysis of the patient with DNMT3A R882H in both leukemic and non-leukemic (remission) cells, some regions of hypomethylation were identical in both samples. This suggests that that focal regions of hypomethylation develop before the onset of leukemia and may therefore represent an ''initiating phenotype'' in cells with DNMT3A R882 mutations.
While these findings provide some mechanistic insights regarding the methylation changes that occur during AML development, the downstream cellular and molecular consequences are still unclear. Our studies revealed only subtle alterations in the other epigenetic modifications we measured at regions with differential DNMT3A activity, and few reproducible differences in transcriptional activity were detected using comprehensive approaches to RNA-seq. Although we observed CpG island hypermethylation in nearly 2,000 gene promoters of AML samples with wild-type DNMT3A, many of the affected genes were not expressed in any AML sample regardless of their methylation status or in normal CD34 cells. Few (if any) of these genes were reproducibly repressed, implying that while promoter hypermethylation might be necessary for the silencing of some genes, it is clearly not sufficient. While it is possible that more subtle expression differences may be identified by examining larger numbers of patients, our analysis failed to identify any clear trends in expression over many hundreds of genes with DMRs at linked promoters, gene bodies, or other potential regulatory elements. These findings suggest that expression phenotypes in AML may arise through common or convergent pathways and emphasize the complex and unpredictable relationship between methylation and gene expression in primary cells (Walsh and Bestor, 1999) . It is also important to note that the paucity of measurable epigenetic consequences is consistent with the fact that patients with DNMT3A mutations can live for years (and even a decade, in the case of the TBRS patient), without measurable abnormalities in hematopoiesis.
DNMT3A has several properties that suggest it is a tumor suppressor. Results from mouse models support this hypothesis, because Dnmt3a-deficient mice can develop lethal hematologic malignancies after the acquisition of cooperating mutations (Celik et al., 2015; Guryanova et al., 2016; Mayle et al., 2015) . These data, and the results from this study, suggest that DNMT3A-dependent methylation, per se, may have tumor suppressor activity. In this model, DNA methylation by DNMT3A could represent a normal, physiologic response that has a suppressive effect on self-renewal. This is supported by the fact that functional loss of Dnmt3a in murine hematopoietic cells causes an expansion of the stem cell pool with serial transplantation (Challen et al., 2011) , implying that Dnmt3a may normally act to suppress self-renewal in progenitor cells. In patients who have clinically apparent AML, this methylation response may represent a ''brake'' that is overwhelmed by cooperating mutations that drive proliferation (although not all AML mutations may behave in this way) (Cole et al., 2016) . The hypermethylation of CpG islands by DNMT3A may represent a molecular ''fossil'' of a failed attempt to restrict proliferation and/or abnormal selfrenewal. In cells with a DNMT3A R882 mutation, the loss of this DNMT3A-mediated braking activity may contribute to leukemia initiation directly, perhaps by allowing the self-renewing HSPC pool to slowly expand. This could increase the risk of transformation to AML simply by increasing the absolute number of self-renewing stem cells that are ''fit'' to accept a cooperating mutation. Although this model may not be relevant for all types of cancer, it does recast the role of de novo DNA methylation in AML development. Experiments designed to test this model may reveal new insights into the roles of de novo DNA methyltransferases-and DNA methylation-in the pathogenesis of AML and other cancers that derive from self-renewing stem cells.
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STAR+METHODS EXPERIMENTAL MODEL AND SUBJECT DETAILS
Primary AML samples All primary AML samples used in this study were from unfractionated bone marrow cells obtained at the time of diagnosis (prior to cytotoxic chemotherapy) at Washington University School of Medicine, using protocols approved by the Human Research Protection Office at Washington University School of Medicine following informed consent in accordance with the Declaration of Helsinki. The collection and processing procedures used to obtain these samples have been described previously (Cancer Genome Atlas Research Network, 2013) . DNMT3A
WT and DNMT3A R882H/C AML samples (UPN numbers 412761, 418499, 427366, 507202, and 296361, 375182, 816067, 868442, respectively, as described in the AML TCGA study) were selected based on the identification of mutations at codon DNMT3A R882, using either exome or whole-genome sequencing data. Other AML groups (see Table S1 ) were based on previously described clinical cytogenetic findings and/or sequencing (Cancer Genome Atlas Research Network, 2013) . The gender and age of all AML patients is shown in Table S1 .
Non-leukemic peripheral blood and bone marrow samples Hematopoietic cells from peripheral blood and bone marrow aspirates were obtained from volunteer donors who provided informed consent for their participation. Bone marrow cells from AML patient 868442 were obtained during a clinical remission (following standard '7+3 0 induction chemotherapy and consolidation therapy with cytarabine). Blood cells from the TBRS patient, and his sibling, were obtained following informed consent provided by the parents. Collection and processing procedures have been described previously (Cancer Genome Atlas Research Network, 2013) , and were approved by the Human Research Protection Office at Washington University School of Medicine. The genders and ages of all donors and patients are shown in Table S1 .
Clinical history of the patient with a heterozygous DNMT3A R882H allele
The proband was 9 years old at the time of analysis (early 2016), and was initially evaluated in infancy for hypotonia, global developmental delay, overgrowth, macrocephaly, and dysmorphic features. The patient was born full term via spontaneous vaginal delivery after an uncomplicated pregnancy to healthy non-consanguineous Caucasian parents. His past medical history was remarkable for two episodes of febrile seizures, hernia repair and orchiopexy, ear tube placements for recurrent ear infections, and tonsillectomy and adenoidectomy due to an abnormal sleep study. He has two healthy brothers and his family history is negative for similar phenotypes or other genetic syndromes. On physical examination, his weight was 62.7 kg (> 99th percentile; 3.5 SD), height was 151.6 cm (> 99th percentile; +2.2 SD), BMI was 27.3 (> 99th percentile; +3 SD) and head circumference was 56.5 cm (> 99th percentile; +2.2 SD). He had mildly coarse facial features with bushy eyebrows, deep set and down slanting eyes, flaring nares, long and smooth philtrum, thin upper lip, large upper incisors, posteriorly rotated ears, and a broad forehead. He also exhibited hyperflexibility of the interphalangeal joints, mild generalized hypotonia, hirsutism on his back, low posterior hairline, and flat feet. Neurodevelopmentally, he exhibits motor and language delays and learning difficulties, for which he receives therapeutic services. His formal IQ testing was $50, and currently his estimated developmental age was about 3-4 years.
METHOD DETAILS
Isolation of hematopoietic cell populations from peripheral blood and bone marrow Fresh peripheral blood and bone marrow samples were processed via ammonium-chloride-potassium red cell lysis, washed, and prepared for fluorescence-activated cell sorting (FACS) for purification of promyelocytes (CD14-, CD15+, CD16low/-) (Elghetany et al., 2004) , monocytes (CD14+), neutrophils (CD14-, CD15+, CD16+) (Elghetany et al., 2004) , and CD34+ cells. The following antibodies were used for FACS: CD34-PE (PE-pool, Beckman Coulter, PN IM1459U), CD14-APC (BD, clone M5E2), CD15-FITC (BD, clone HI98), CD16-PE (BD, clone 3G8), CD33-APC (eBioscience, clone WM-53), CD3-V450 (eBioscience, clone OKT3), and CD19-PE (BD, clone HIB19). Purified cells were then immediately submitted for DNA or RNA extraction using Qiamp DNA mini and Zymo Micro RNA kits, respectively, and then used as input for the genomic analyses below.
Ex vivo expansion of hematopoietic stem/progenitor cells from AML patient 868442 during remission Remission cells from AML patient 868442 were obtained from cryopreserved bone marrow aspirate specimens collected 907 days after AML diagnosis. Approximately 20 million cryopreserved cells were thawed and diluted in 40% fetal calf serum, collected via centrifugation, and then cultured overnight in hematopoietic expansion media (IMDM, 10% fetal calf serum, 10mM L-glutamine and 1X penicillin/streptomycin with recombinant human cytokines: 10 ng/mL SCF, 25 ng/mL FLT3 ligand, 20 ng/mL TPO, 10 ng/mL IL-3, and 10 ng/mL G-CSF). Cultured cells ($4 million viable cells) were then collected and stained with a panel of FITC-conjugated lineage markers (CD3, CD19, CD14, and CD16; specific antibodies are the same as above), CD34-PE (antibody is the same as above), and CD38-APC (BD, HIT2). Lineage -/CD34 + /CD38 -were sorted on a Sony Synergy SY3200 sorter at 1 cell per well into 96-well plates (334 total sorted cells into 4 plates) containing AFT024 stromal cells (ATCC: SCRC-1007) irradiated at 2000 cGy and plated at a density of 2.5 3 10 4 cell per well of a 96-well plate 24 hr prior to the cell sorting, and in 100 mL the above expansion media. The culture plates were maintained at 37 C with 5% CO 2 and ambient oxygen. Cultures were supplemented with 50 uL fresh media on days 5 and 10, and an additional 100 uL of media was replaced on day 17. On day 21, wells with visible hematopoietic cell growth were transferred to a 24-well plate without AFT024 feeder cells and grown for 9 additional days in expansion media. On day 27, 200 uL was removed from each of 58 wells and DNA was prepared for PCR-sequencing by centrifuging the dilute cell suspension at 500 g for 5 min and resuspension in 10 uL single cell lysis buffer (10 mM Tris-HCl pH 7.6, 50 mM NaCl, 6.25 mM MgCl 2 , 0.045% NP40, 0.45% Tween-20) with 1 uL proteinase K. Cells were lysed 55 C for 1 hr and 95 C for 15 min, and 3 uL of lysate was used in a 20 uL PCR reaction (NEB Phusion master mix) to amplify a 339 bp product spanning codon 882 of DNMT3A (primers: TCCTGCTGTGTGGTTAGACG and TCTTCTGGGTGCTGATACTT; PCR conditions: 98 C for 30 s, then 35 cycles of 98 C 10 for seconds, 60 C for 10 s, and 72 C for 15 s, followed by 72 C for 7 min). PCR reactions were purified via spin columns (MachereyNagel PCR cleanup kit), and used as input for 20 uL Sanger sequencing reactions with 5 pmol forward primer, followed by capillary electrophoresis, which yielded unambiguous sequencing results for 44 of the 58 wells. On day 30, cells from these 44 wells were pooled according to genotype, counted, and a subset of the cells removed for analysis via flow cytometry for CD45-PerCPCy5.5 (eBioscience, 2D1), CD34-PE (as above), CD33-APC (eBioscience, clone WM-53, CD15-FITC (as above), CD11b-V450 (BD, clone ICRF44). The remaining cells were used for DNA and RNA extractions using the QIAGEN QIAmp DNA Mini Kit and Zymo RNA Micro kits, respectively. Genotypes of the pooled cells were confirmed with a second PCR-sequencing experiment using different primers and modified PCR conditions (primers: TTTATAAAGGACAGAAGATTCGGCAGAA and CCTTACACACACGCAAAATACTCCTT; PCR conditions: 98 C for 30 s, then 35 cycles of 98 C 10 for seconds, 58 C for 30 s, and 72 C for 30 s, followed by 72 C for 5 min). DNA and RNA from the pools was used as input for bisulfite sequencing and RNA-seq, as described below.
Bisulfite sequencing, data processing, and analysis Whole-genome bisulfite sequencing was performed using either the EpiGnome/TruSeq DNA Methylation Kit (Illumina; used for all AML samples, remission cells, and normal donor samples) or Swift Accel-NGS Methyl-Seq (TBRS patient and sibling) library preparation kits following the manufacturer's protocols. For EpiGnome libraries, 3-4 libraries were prepared for each sample using 50 ng of input DNA by denaturing the DNA at 98 C for 10 min followed by bisulfite conversion at 64 C for 2.5 hr and DNA clean-up with the EZ DNA Methylation Gold Kit (Zymo Research). Library molecules are then generated via DNA synthesis of the converted DNA using random-primed synthesis, digestion of random primers, 3 0 tagging, purification using AMPure beads, and limited cycle amplification (10 cycles) to incorporate sample-specific index sequences. For libraries generated with the Swift kit, a single library was produced for each sample using 50 ng of DNA. Library preparation was performed by first shearing the DNA with a Covaris S220 (duty factor 10%, peak incidence power 140W, 200 cycles/burst for 67.5 s), followed by DNA concentration with the Zymo Clean and Concentrate Kit, and bisulfite conversion and purification with the EZ DNA Methylation Gold Kit (Zymo Research). Molecules were then tagged and DNA synthesis was performed using Adaptase and extension reactions, and the ligated with sequencing adapters. Purification was performed using AMPure beads and final library molecules were amplified for 6-7 cycles using oligomerss with samplespecific index sequences. All libraries were assessed via Qubit and Agilent Bioanalyzer prior to pooling and sequencing on 1-2 lanes (per unique sample) of Illumina HiSeq 2500 instruments to obtain 2x125 bp reads. Initial data processing. All bisulfite sequence data were mapped with BSMap (Xi and Li, 2009) using with parameters '-q 20 -u -v 0.08 -w 100 -z 33 0 , after which methylation values were calculated with Bis-SNP according to recommended procedures, including read realignment, quality score recalibration, and filtering (Liu et al., 2012) . Methylation values on both strands for all CpGs were then used as inputs for the following analysis procedures, which were applied separately to the DNMT3A R882H/C and DNMT3A WT AMLs, remission cells, and the TBRS patient and sibling: Identification of unmethylated regions. Data were reformatted to serve as input to the 'hmr' program in the 'methpipe' program suite (Song et al., 2013) , which was used to identify unmethylated regions in each sample. Regions identified by this program were further filtered to retain only those with > 5 CpGs and which possessed coverage-weighted mean methylation values < 0.2. 'Consensus' unmethylated regions were identified as regions > 500 bp that were called unmethylated by the above criteria in all DNMT3A R882H/C and DNMT3A WT AMLs and CD34 cells. Unmethylated regions within 100 bp were merged into a single region. Identification of differentially methylated regions (DMRs). The program 'metilene' (Jü hling et al., 2016) was used to analyze the raw methylation ratios at all CpGs to identify differentially methylated regions (DMRs) with > 10 CpGs and a mean methylation difference between the same groups of > 0.2. DMRs were filtered to retain those with FDR < 0.05, and adjacent DMRs < 50bp apart were merged. Following these procedures, methylation data from individual CpGs were imported into R as bsseq objects (Hansen et al., 2012) for manipulation and analysis, which included 'smoothing' using the BSmooth function with the parameters 'ns = 35 and h = 500' to impute missing methylation values for visualization; all statistical procedures and analysis used raw methylation ratios (or methylation counts) from individual CpGs, or summed data for CpG clusters or DMRs. Classification of 'hypomethylated' versus 'hypermethylated' DMRs. DMR classification was performed using the 'dist' function in R to calculate a Euclidean distance matrix of the coverage-weighted mean methylation values for each hypomethylated DMR (using data summed across all CpGs contained within the DMR boundaries) for the core DNMT3A R882H/C , DNMT3A WT , and CD34 samples. Each DMR was called either 'hypomethylated' or 'hypermethylated' based the relationships between these distances, which can assume three different topologies: 1) methylation of DNMT3A R882H/C and CD34 are closely related and the DNMT3A WT value was the outlier, which was called 'hypermethylated', or 2) methylation of DNMT3A WT and CD34 are closely related and the DNMT3A R882H/C value was the outlier, which was called 'hypomethylated', or 3) DNMT3A
WT and DNMT3A R882H/C are more closely related to each other and CD34 cells are the outlier, which was called 'hypermethylated' if both were hypermethylated (since this scenario represents less hypermethylation in the DNMT3A R882H/C AMLs), and 'hypomethylated' if both were hypomethylated (since this represents exaggerated methylation loss in DNMT3A R882H/C AMLs). Subsequent statistical comparisons of methylation at DMR loci were performed using a chi-square test on the raw methylation counts summed across all CpGs contained within the DMR, and p values were corrected for multiple testing within each set of comparisons using the method of Benjamini and Hochberg (1995) . Overlap with CpG islands and annotated genes was performed using the CpG island track from the UCSC genome browser, and gencode version 19 annotations based on the hg19/GRCh37 human reference (http://www.gencodegenes.org/releases/19.html). Statistical enrichment analysis for specific regions of interest was performed via chi-square test between the number of CpGs in the region of interest (e.g., CpG islands) versus the number of non-DMR CpGs in the region of interest. The background frequencies in these calculations included only CpGs with coverage in the WGBS datasets. Overlap with conserved epigenetic features. Enrichment for epigenetic features identified in the primary AML samples and CD34 cells (see below for methods) was determined empirically using the GAT program (Heger et al., 2013) , to identify significant overlaps between DMR regions and supported peaks in the epigenetic data. A file of regions with coverage in the WGBS data was also used to derive background frequencies used to calculated the empirical p values.
Chromatin accessibility profiling (ATAC-seq) Transposase-mediated chromatin accessibility profiling of primary AML cells was performed using the Nextera library preparation kit as described in Buenrostro et al. (2013) using 75,000-150,000 viable cells per sample. Briefly, cells were pelleted, washed once in 50 uL cold 1X PBS, and then resuspended in 50 uL cold ATAC lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.1% Igepal CA-630). Lysed cells were then immediately centrifuged at 500 x g for 10 min at 4 C, and cell nuclei were resuspended in 25 uL Nextera tagmentation buffer (Illumina) for transposition with 2.5 uL of Nextera transposase enzyme (Illumina) in a total volume of 50 uL at 37 C for 30 min. DNA was purified with QIAGEN MinElute columns before amplification with sample-specific primers for a total 9-12 cycles (the exact cycle number was determined via qPCR analysis after 5 cycles). Libraries were either size-fractionated into small (< 300 bp) and large (300-800 bp) libraries, or a single library (100-500 bp) and sequenced on Illumina 2500 instruments (2-4 libraries per lane) to obtain either 2x50 or 2x125 bp reads. Data were QC'ed by visualizing read length periodicity, and libraries without observable nucleosome exclusion patterns were repeated. Initial data processing and analysis. Reads were mapped with the bwa mem program (Li, 2013) and the resulting data were merged and filtered to retain unique, properly paired reads mapping to the nuclear genome (using the hg19/GRCh37 human reference). Data were subsequently processed with homer (Heinz et al., 2010) to format tag data, identify peaks, and obtain raw tag counts via the commands 'makeTagDirectory', 'findPeaks < input > -tbp 3 -minDist 50 -region -fragLength 50 -o < peaks > ', 'makeUCSCfile < input > -fragLength 50 -bigWig ref.fa -style dnase -o < output > ', and 'annotatePeaks -raw', respectively. DESeq2 (Love et al., 2014) was used to calculate normalized counts at all identified peaks across all samples, and to perform statistical comparisons between DNMT3A R882H and DNMT3A WT AMLs at these peaks.
individually. Signal heatmaps were produced by rescaling all values from no signal to the 99 th percentile signal value (and values above this were capped); scaling was performed using all values for each signal type (i.e., H3K4me1 signals for all samples).
Total RNA-sequencing, processing, and analysis Total RNA-sequencing of AML samples, normal bone marrow cells, and remission cells was performed using the Illumina TruSeq Stranded Total RNA Library Kit on DNase-treated RNA. Samples were ribo-depleted, purified, and fragmented at 94 C for 8 min. First-strand and second strand cDNA synthesis was then performed, followed by bead-based DNA purification, A-tailing, and adaptor ligation. Library fragments were then bead-purified and amplified 7-8 cycles with sample-specific indexed primers. Sequencing was performed on an Illumina 2500 instrument to obtain 2 3 100 bp or 2 3 125 bp reads. Sequence data were processed from the raw sequencing reads using the tophat (version 2.0.8, (Trapnell et al., 2009) ) to generate split read alignments, and expression values (FPKM) for gencode version 19 annotations were calculated with stringtie (Pertea et al., 2015) using default parameters for stranded, paired-end data. Raw read counts for annotated genes were obtained with 'featureCounts ' (Liao et al., 2014) , and normalized using DEseq2 (Love et al., 2014) . Differential analysis of exon usage was performed using DEXSeq (Li et al., 2015) following the recommended procedures. Expression versus methylation difference plots were generated using the difference in mean expression (log 2 normalized counts) between the two indicated sample groups (or individual samples) and the difference in either the indicated gene element (promoter, defined as À2000 to +500 from the TSS, or the entire gene length for the gene body), or the specific DMR region overlapping that gene element (i.e., only the CpGs within the boundaries of the DMR, which overlaps the specified gene element).
Small (17-200 nt) RNA sequencing Small RNA species were sequenced using total RNA from the primary AML samples and normal donor samples using the NEBNext Small RNA Library Prep Kit for Illumina following the recommended protocol. Briefly, 100 ng of DNAase-treated input RNA was used for 3 0 ligation, RT primer hybridization, reverse-transcriptase, and 5 0 ligation reactions. Library molecules were then amplified with sample-specific indexed adapters for 12-15 cycles, and then size selected via electrophoresis on a bluepippin instrument to obtain molecules with library inserts between 17 and 200 nucleotides. Libraries were then multiplex sequenced on a MiSeq instrument, and sequencing reads were mapped with bwa mem (Li, 2013) using the parameters '-k 15 -T 17' to yield alignments for short library inserts. Read counts for annotated genes in the gencode version 19 database were then generated using 'featureCounts' (Liao et al., 2014) , with the parameters '-s 1 -t exon -g transcript_id -Q 1 -O' to accurately count reads in small RNA annotations that are occasionally embedded in larger gene annotations. Normalized counts and differentially expressed species were obtained with DESeq2 (Love et al., 2014) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using either the software indicated above or in R. Hypothesis testing in R was performed using either t tests or chi-square tests, where indicated. All clustering analysis was performed in R using Ward's method (Murtagh and Legendre, 2013) .
DATA AND SOFTWARE AVAILABILITY
All processed sequence data (i.e., bigwig files of coverage and peak locations for ATAC-seq and ChIP-seq, and WGBS CpG coverage and methylation levels) can be found at this URL: https://wustl.app.box.com/s/6fvifntz6golh4vu52epkfqxeyd0vqmk. Raw sequence data from samples obtained for this study will also be deposited in dbGaP (https://www.ncbi.nlm.nih.gov/gap) under the accession number dbGaP: phs000159. Per the protocol approved by the Human Research Protection Office at Washington University School of Medicine (HRPO#01-1014/201011755), sequence data in this repository may only be shared with qualified researchers who have received prior approval from individuals that monitor the use of the data. For this reason, potentially identifying genetic data will only be deposited in the controlled access database at dbGaP. Consent documents containing the information regarding data access can be found in Methods S1. Figure S1 . Related to Figure 1 
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